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ABSTRACT
Purpose The Translational Research and Patients safety in Europe 
(TRANSFoRm) project aims to integrate primary care with clinical research whilst 
improving patient safety. The TRANSFoRm International Research Readiness sur-
vey (TIRRE) aims to demonstrate data use through two linked data studies and by 
identifying clinical data repositories and genetic databases or disease registries 
prepared to participate in linked research.
Method The TIRRE survey collects data at micro-, meso- and macro-levels of 
granularity; to fulfil data, study specific, business, geographical and readiness 
requirements of potential data providers for the TRANSFoRm demonstration stud-
ies. We used descriptive statistics to differentiate between demonstration-study 
compliant and non-compliant repositories. We only included surveys with >70% of 
questions answered in our final analysis, reporting the odds ratio (OR) of positive 
responses associated with a demonstration-study compliant data provider.
Results We contacted 531 organisations within the Eurpean Union (EU). Two 
declined to supply information; 56 made a valid response and a further 26 made 
a partial response. Of the 56 valid responses, 29 were databases of primary care 
data, 12 were genetic databases and 15 were cancer registries. The demonstration 
compliant primary care sites made 2098 positive responses compared with 268 
in non-use-case compliant data sources [OR: 4.59, 95% confidence interval (CI): 
3.93–5.35, p < 0.008]; for genetic databases: 380:44 (OR: 6.13, 95% CI: 4.25–8.85, 
p < 0.008) and cancer registries: 553:44 (OR: 5.87, 95% CI: 4.13–8.34, p < 0.008).
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ABBREVIATIONS
IT - information technology; EMR - electronic medical 
records; TRANSFoRm - Translational Research and Patients 
safety in Europe; TIRRE survey - TRANSFoRm International 
Research Readiness survey; IBM SPSS - IBM Statistical 
Package for Social Sciences; eHR - electronic health 
record; OR - odds ratio; ICD - International Classification of 
Disease; ICPC - International Classification of Primary Care; 
SNOMED - Systematised Nomenclature of Medicine; CTv3 
- Clinical Terms Version 3; ATC - Anatomical Therapeutic 
Chemical; HL7 - Health Level-7; RIM - Reference Information 
Model; CDISC - Clinical Data Interchange Standards 
Consortium; BRIDG - Biomedical Research Integrated 
Domain Group; CSV - Comma Separated Values; CPRD - 
Clinical Practice Research Datalink.
INTRODUCTION
Large databases of health data are widely used for research 
but less often combined.1 Linked data facilitates better 
measurement of clinical performance and patient health 
outcomes in health care systems.2 Technical challenges 
of linking data are mostly considered to be the key bar-
rier of integrating disparate heterogeneous data sources.3 
Data privacy legislations can considerably hinder research 
in a multinational setting.4 Data collected within primary 
care have been computerised since the 1990s5 with data 
widely used for research,6 but with relatively little linkage 
of data beyond disease-specific programmes in individual 
localities. In the United States, the federal electronic medi-
cal records mandate aims not only to save money but also 
to modernise health information technology (IT). A team of 
RAND Corporation researchers projected in 2005 that a 
move towards health IT could potentially save $81 billion. 
However, this saving has far from materialised and despite 
the recommendations, spending in the US has increased 
over the past 9 years by $800 billion.7 The increase in 
spending was, in part, attributed to the slow adoption of 
health IT systems that are neither interoperable nor easy 
to use.
The Translational Research and Patient Safety in Europe 
(TRANSFoRm) project aims to reduce barriers to conducting 
research using routine healthcare data across Europe.8–10 
The European eHealth Action Plan prioritises interoperabil-
ity between health records so that internationally comparable 
data can be collected on the quality of care and for research.11 
The TRANSFoRm International Research Readiness 
(TIRRE) survey was developed and designed to collect 
information about these data sources with the primary aim of 
assessing the preparedness of disease registries, throughout 
Europe, to conduct linked research using the TRANSFoRm 
project (Appendix 1). The TRANSFoRm requirements for 
the TIRRE instrument were that it could assess the feasibil-
ity of conducting two simulated studies (use-cases): one on 
the genetics of response to oral anti-diabetic medication; the 
other on the relationship between anti-indigestion medica-
tion, Barrett’s disease, oesophageal cancer and the quality 
of life. The ‘use-cases’ were designed to capture how primary 
care recorded oesophageal reflux might be a prodrome of 
cancer; and any genetic predisposition to complications of 
people with type 2 diabetes.6
Initially, we focussed on whether a repository had the 
required dataset ‘data readiness’ or the technical mechanism 
to extract data in the format needed for analysis ‘record readi-
ness’. The different levels are ascertained by reviewing the 
metadata captured from the survey. The overall assessment 
gives an indication as to whether a database is capable of con-
tributing to linked research (i.e. ‘linked research readiness’). 
However, a stakeholder analysis, expert opinion12 and pilot 
data collection,13 all pointed toward the necessity to take a 
broader approach and to include socio-cultural and business 
process aspects of readiness. We consequently developed 
a more systematic approach to analysing the requirements 
for generic data linkage studies, as well as those specific to 
the TRANSFoRm use-cases.14 Our pilot TIRRE survey indi-
cated that this instrument identified databases that could be 
used to conduct the more sophisticated translational and 
biomedical research planned within the TRANSFoRm proj-
ect. Consequently, the final version of TIRRE collects data at 
three levels of granularity – the micro or data level; the meso- 
or record system level and the macro or health service level. 
TIRRE also includes study specific questions defined from 
the oesophagitis and diabetes use-cases. This study reports 
the results of the first TIRRE survey.
METHOD
Sampling and data collection
Our initial contact was to the health ministry of each EU coun-
try and to National Primary Care Organisations. Subsequent 
strategies included trying to identify sites through Internet and 
Medline searches, and snowball sampling through contacts 
made or work references. We also contacted National and 
European informatics and research networks. We identified 
sites across Europe willing to participate in the survey by con-
tacting them through email or web-form and we then followed 
this up with a phone call. We exported these data from the 
Conclusions TIRRE comprehensively assesses the preparedness of data repos-
itories to participate in specific research projects. Multiple contacts about hypotheti-
cal participation in research identified few potential sites.
Keywords: medical informatics, family practice, medical records systems, 
electronic health records, diabetes mellitus, Barrett’s disease
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completed online questionnaires directly into either Microsoft 
Excel or into Statistical Package for Social Sciences (IBM 
SPSS). We categorised ‘non-compliance’ as a respondent 
who partially completed the online survey, answering <70% 
of the questions; or as a respondent with whom we had made 
telephone contact initially was unavailable for their telephone 
interview or failed to proceed to online completion of the 
survey. A major component of the workload in this project 
involved identifying potential survey respondents.
Micro-, meso- and macro-level
The broad scope of the survey emerged from a series of 
workshops and is composed of a wide range of questions 
designed to assess how data might be linked, the data itself, 
extraction methods and social and organisational influ-
ences.15,16 The final instrument contained 160 questions 
divided into a framework which consisted of micro-, meso-, 
macro- and study-specific levels.
 • The first section covered micro-level issues and 
was concerned with the data source, the data itself, 
metadata, the potential for linkage or achieving 
semantic interoperability between data sources17 and 
details of how many studies have been published 
using the data.
 • The meso-level explored the data extraction,18 the 
architecture for the computerised medical record and 
other data repositories,19 audit trails and the size of 
the database.
 • The macro-issues related to the nature of the health 
system, socio-cultural factors and issues relating to 
the funding, purpose and restrictions on the use of 
the data.
 • Study-specific questions make up the final part of 
the survey instrument (Supplementary data file, 
Table S1), these were designed to identify sites that 
were eligible to participate in the use-cases in pairs of 
primary care and genetic, or primary care and cancer 
registry data.
We described the coding systems used to store data, 
including drug dictionaries and any standards used (the aim 
was to determine whether there were a small number of 
possible combinations of coded data to identify within data 
repositories and the mechanisms for achieving interoper-
ability), the number and details of eHR vendors, vendors of 
communications and data processing applications routinely 
used (including their international scope, coding systems 
offered and if they had common data export formats) along 
with organisational, policy, cultural or legislative restrictions 
on data reuse.
Use-case specific
We analysed the process of conducting two use-cases and 
defined the studies using a framework which defined the 
micro-, meso- and macro-levels of data and process infor-
mation required to conduct successful linked research, 
where multiple data sources are semantically integrated. We 
summarised the sites eligible to participate in the use-cases 
in pairs of primary care and genetic or primary care and can-
cer registry data. If the database can support a use-case, 
we consider the site as a use-case compliant site and if it 
cannot support, we define the site as a non-use-case site. 
Registries were only eligible if they provided a valid response 
to the questionnaire. We required as much of the survey to be 
completed as possible as each part of it was determined from 
our requirements analysis. We defined a valid response to be 
one which answered >70% of the questions. Key compulsory 
answer questions which defined compliance provided infor-
mation such as valid contact details, a link to another data-
set, size of the dataset, data model and details of the coding 
system, the likely lead time in any approval process and that 
they have use-case variables available. All sections of the 
questionnaire provided significant and useful information to 
determine if the database was use-case specific.
Reporting and analysis
We compared the responses from databases that proved eli-
gible to participate in the use-cases with those who were not. 
We wanted to explore whether it was more likely that those 
associated with eligibility would give a positive response to 
questions than those who were not deemed eligible. A valid 
response provided by the respondent is considered a positive 
response. The purpose of this exercise was to identify any 
questions that were not purposeful and to reduce the number 
of questions. We identified and reviewed any questions that 
were not answered positively by any of the use-case eligible 
respondents on the basis that they were not discriminatory of 
eligibility to participate in either of the studies.
Statistical methods
We used descriptive statistics (i.e. measures of frequency) to 
describe response rates and quote odds-ratios (ORs), 95% 
confidence intervals (CIs) and used tests of proportion to 
report whether sections of the questionnaire helped to dis-
criminate between those able to conduct the use-case or not.
Ethics statement
There was no formal ethics board review. This survey only 
seeks to report information about the capacity and capability 
of information sources to be combined to conduct research 
studies and does not involve any access to personal data. 
However, the TIRRE survey does check whether data 
sources collect individual consent and if they contain strong 
identifiers and if there are restrictions on the use of data.
RESULTS
Sample and data collection for use-case 
specific defined studies
We made many contacts but received few responses. We 
contacted 531 different organisations, and later individuals in 
EU countries (including eHR vendors) and received 56 valid 
responses. Of the health ministries we contacted, seven pro-
vided useful information and a further five responded but could 
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not provide any helpful information. Only two site represen-
tatives declined to participate at this stage (Supplementary 
data file, Table S2).
eHR vendors
We also collected details of the national or international 
eHR vendors with a significant presence in one or more EU 
countries. We contacted 17 companies identified initially, as 
well as any reported by survey respondents. Nine of these 
eHR vendors had a presence in more than one country. Two 
of those contacted started to complete the TIRRE survey 
instrument but failed to complete the questionnaire. We 
also approached nine vendors listed by site representa-
tives who completed the questionnaire but they once again 
expressed no interest in participating in the survey. They did 
suggest they might consider completing the survey in the 
future if and when we had something more definite to offer. 
Few vendors responded; however, when they did reply to 
the survey, their responses to the questions posed provided 
useful detail.
Telephone and online completion of the 
survey
Of the 531 organisations we made contact with, 45 respon-
dents commenced but did not complete the TIRRE survey 
online (Supplementary data file, Table S3) and 26 made a 
partial response during telephone enquiries but were then 
either unavailable for their telephone interview or failed to go 
ahead and complete the online survey. The initial telephone 
interviews took 1.5 hours and with experience still took 50–75 
minutes. The feedback from the pilot survey suggested that 
the process took too long and that there was very little incen-
tive for the respondent for completing the survey. While this 
drawback of the survey could have possibly caused a bias 
for the responses collected, we consider this as a valuable 
learning to consider in similar database profiling activities 
conducted in the future.
Completion of the survey
The valid surveys were on an average returned with 76% 
of the questions completed and this was consistent across 
the three respondent groups. Looking at the survey by cat-
egory, the Data source and Record system sections were 
the only ones that fell below the 75% level (many sections 
were returned with above 90% of the questions completed). 
The main reason for this was the variation in the skip logic 
for individual respondents in these sections of the ques-
tionnaire (Supplementary data file, Table S4). There was a 
little difference between the sites which we had identified 
as eligible to participate in the use-cases and those we had 
identified as not eligible (77% use-case sites versus 75% 
non-use-case sites).
Results micro-level data
The greater the number of coding systems in use, the harder 
it will be to achieve semantic interoperability; therefore, the 
micro-level data collection was primarily concerned with col-
lecting information about the coding systems the repositories 
used. We found that the WHO International Classification of 
Disease (ICD)20 was the most common coding system used 
by 71% (n = 39) of respondents. ICD-10 (n = 32) was used 
by 82%; 13% (n = 5) used ICD-9; 23% (n = 9) used an ICD 
modification and 5% (n = 2) did not respond (Supplementary 
data file, Table S5).
The second most used coding system was the WHO 
International Classification of Primary Care (ICPC), this was 
used by 20% (n = 11) of respondents. Eighty-two percent 
(n = 9) of those using ICPC used ICPC-2 and 18% (n = 2) 
used ICPC-1, none reported using an ICPC modification 
(Supplementary data file, Table S6). The third most com-
mon coding system was the Systematised Nomenclature of 
Medicine (SNOMED),21 which was used by 13% (n = 7) of all 
the respondents; 44% (n = 4) of those using SNOMED used 
the Clinical Terms version; 33% (n = 3) used the Reference 
Terminology version and 22% (n = 2) did not respond 
(Supplementary data file, Table S7).
One of the least common coding systems used was the 
Read Coding system [version2 – 5-byte and the Clinical 
Terms Version 3 (CTv3)] and these were only used by the 
seven UK repositories. They represented 9% (n = 5) and 4% 
(n = 2) of all respondents, respectively; 87% (n = 50) did not 
respond (Supplementary data file, Table S8).
The survey highlighted that there was a great variety in 
the number of drugs dictionaries utilised by the reposito-
ries and this is one potential barrier to achieving semantic 
interoperability. Sixty percent (n = 33) of respondents said 
that they have a coding system for drugs (Primary care 
83%, n = 24; Cancer 33%, n = 5; Genetic 36%, n = 4). 
Of these; 76% (n = 25) use the Anatomical Therapeutic 
Chemical classification system;22 9% (n = 3) use Multilex; 
12% (n = 4) responded ‘other’ and 3% (n = 1) responded 
‘no data’ (Supplementary data file, Table S9). We were 
interested to know whether it was possible to extract infor-
mation about the administration of drugs and we asked 
respondents if it was possible to extract data about daily 
dose and administration route from their database. Only 
around one-third of the Primary care and Cancer registries 
could extract data of this nature, while none of the genetic 
databases held this information (Supplementary data file, 
Table S10).
The survey was designed to assess what systems 
the registries had in place to achieve interoperability and 
to ensure data quality. Thirty-four percent (n = 19) of 
respondents had no system at all; only 5% (n = 3) used 
Health Level-7 (HL-7), an international interoperability 
organisation who’s Reference Information Model under-
pins much interoperability in healthcare; 2% (n = 1) used 
the Clinical Data Interchange Standards Consortium 
(CDISC);23 none used the Biomedical Research Integrated 
Domain Group (BRIDG)24 and 52% (n = 29) used an 
‘In-house or other’ system (Table 1). Nearly, all (93%, 
n = 52) of the respondents either had no system in place or 
used an in-house system or provided no data.
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Data collection meso- and socio-cultural 
levels
Data extraction at this level was concerned with record level 
issues. The majority of respondents (82%; n = 45) have 
the ability to extract data in standardised formats such as 
Comma Separated Values, Excel and full text. All of the 
respondents have at least one appropriate format. The data 
collected have a wide application and this is reflected by 
the diverse nature of the information stored within these 
repositories which ranges from research to mortality records 
(Table 2).
The respondents reported that socio-cultural influences 
had a small but significant impact on the validity of their data. 
These factors included ethical, religious and legal factors 
(Table 3); these might delay or prevent participation in the 
TRANSFoRm studies.
Socio-cultural factors, which include legal and ethical 
constraints, as well as influences on diagnosis, and organ-
isational components of the health system from which the 
data originates are often barriers to conducting research. 
In summary, 71% (n = 39) of respondents use ICD and 20% 
(n = 11) use ICPC; however, 86% (n = 48) do not use one of 
the three main systems for ensuring data quality; 29% opt 
instead for an in-house system. Very few sites are adopt-
ing national standards for interoperability in linking data. 
Whilst multiple drug dictionaries were used, 66% (n = 10) 
of cancer repositories did not use them. Extract formats 
for data were standardised and only 3% (n = 6) of respon-
dents chose to use a non-standard format. Data were 
not forthcoming from eHR vendors (n = 40). Repositories 
had a broad range of applications for their data, the most 
important was research (49%, n = 51). The most common 
socio-cultural influence that could potentially affect the 
validity of their data was ethical (10%, n = 7) and social 
(10%, n = 7) factors although 49% (n = 36) reported no 
social issues at all.
Difference in response depending on 
eligibility
Data sources that were non-use-case eligible tended to pro-
duce much fewer positive responses than those that were eli-
gible. Overall, the repositories identified as potentially being 
use-case eligible made 2098 positive responses to question-
naire items compared with 268 from non-use-case eligible 
data sources (OR: 4.59; 95% CI: 3.93–5.35; p < 0.008); for 
genetic databases, the respective figures were 380:44 (OR: 
6.13; 95% CI: 4.25–8.85; p < 0.008) and for cancer registries, 
they were 553:44 (OR: 5.87; 95% CI: 4.13–8.34; p < 0.008); 
the full results are in Table 4.
Data repositories capable of participation in 
the survey
Of the 56 valid responses, there were 15 pairs eligible to com-
plete one or other of the use-cases. The 56 valid responses 
were made up of 29 databases of routine primary care 
data, 12 genetic databases and 15 cancer registries. From 
the valid responses, we were able to identify the location of 
databases with the potential to participate in the research 
studies. We identified five locations for linking primary care 
databases with genetic databases and 10 for linking primary 
care databases with cancer registries. The 15 eligible sites 
were spread across 11 countries (Supplementary data file, 
Table S11).
No system HL-7 CDISC BRIDG In-house or other No data
n % n % n % n % n % n %
Primary care 9 31 0 0 0 0 0 0 18 62 2 7
Cancer registry 4 25 2 13 1 6 0 0 7 44 2 12
Genetic ‘Biobank’ 6 55 1 9 0 0 0 0 4 36 0 0
Total 19 34 3 5 1 2 0 0 29 52 4 7
Table 1 Systems used to ensure data quality
Research Mortality records
Financial 
monitoring
Quality 
performance 
monitoring
Other
n % n % n % N % N %
Primary care 27 43 5 8 8 13 14 23 8 13
Cancer registry 13 45 4 14 3 10 4 14 5 17
Genetic 
‘Biobank’ 11 79 0 0 1 7 0 0 2 14
Total 51 49 9 9 12 11 18 17 15 14
Table 2 The aims of the data source for the data collected
Journal of Innovation in Health Informatics Vol 25, No 4 (2018)
Liyanage et al. An instrument to identify computerised primary care research networks, genetic and disease registries prepared to conduct linked research 212
No social 
issues Legal Ethical Social Economic Political Religious Other No Data
n % n % n % N % n % n % n % n % n %
Primary 
care 20 57 1 3 1 3 5 14 4 11 0 0 0 0 2 6 2 6
Cancer 
registry 9 43 3 14 3 14 0 0 2 10 0 0 1 5 1 5 2 9
Genetic 
‘Biobank’ 7 40 1 6 3 18 2 12 0 0 1 6 2 12 1 6 0 0
Total 36 49 5 7 7 10 7 10 6 8 1 1 3 4 4 6 4 5
Table 3 Socio-cultural influences on the validity of the data
Level Category Use case eligible
Not use case 
eligible OR
95% CI 
lower 
bound
95% CI 
upper 
bound
p
Primary care data sources
MICRO Data source 654 72  2.43 1.77  3.33 0.000
Data interoperability
499 137  5.19 4.13  6.52 0.000
Subtotal 1153 209  4.47 3.74  5.34 0.000
MESO Record system 56 32  4.38 2.33  8.21 0.000
MACRO Organisational 564 0
Socio cultural 174 6 14.50 5.91 35.59 0.000
Subtotal 738 6 12.75 5.36 30.33 0.000
STUDY Use-case specific 151 21  0.49 0.20  1.19 0.000
Overall 2098 268  4.59 3.93  5.35 0.000
Genetic data/Biobanks
MICRO Data source 133 13  4.18 2.04  8.54 0.000
Data interoperability
73 17  7.05 3.89 12.79 0.000
Subtotal 206 30  7.32 4.70 11.39 0.000
MESO Record system 16 5  7.47 1.39 40.25 0.000
MACRO Organisational 106 0
Socio cultural 32 6  0.76 0.14  4.25 0.395
Subtotal 138 6  0.63 0.12  3.20 0.001
STUDY Use-case specific 20 24  2.22 0.52  9.51 0.007
Overall 380 44  6.13 4.25  8.85 0.000
Cancer registries
MICRO Data source 210 5 12.86 4.89 33.82 0.000
Data interoperability
128 23  7.97 4.77 13.33 0.000
Subtotal 338 28  8.77 5.69 13.52 0.000
MESO Record system 13 11  5.32 0.94 29.99 0.014
MACRO Organisational 114 0
Socio cultural 45 5  3.00 0.88 10.18 0.000
Subtotal 159 0
STUDY Use-case specific 43 0
Overall 553 44  5.87 4.13  8.34 0.000
Table 4 Positive responses to the questionnaire sections – comparing non-use case 
eligible and use-case-eligible data sources 
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Details of the eligible sites
The sites had a total of around 1.5 million potential patients 
eligible to participate in this research; over 30,000 in the 
genetics of diabetes use-case and over 1 million to par-
ticipate in Barrett’s disease, oesophageal cancer and the 
prescription of 30 medicines used to treat dyspepsia use-
case. The country of origin, the website for these sites, the 
main coding system used and the expected delay in ethical 
approval are shown in Tables 6. We sometimes found con-
tradictions between the data sources which indicated that 
they could supply linked data and several of the participants 
were, on closer questioning, only linking on a pilot basis; we 
have shaded out in grey the sites which are not currently 
active. The outcome of this process is that we have iden-
tified one fully functional location able to run the diabetes 
use-case (Table 5) and five pairs of locations able to run 
Barrett’s disease use-case (Table 6). The one able to run the 
diabetes use-case is the Wellcome Type 2 Diabetes study 
group in Scotland. The five locations that can run the sec-
ond use-case are as follows: Finland, Germany (Bremen), 
Norway, UK (General Practice Research Database), UK, 
Scotland (pilot).
DISCUSSION
Principal findings
The TIRRE survey has been completed by 56 data-reposito-
ries across Europe and six outside the EU. We have devel-
oped a usable instrument which can assess their potential to 
take part in linked data research. There were no equivalent 
International sites available to conduct this type of research. 
A challenge was to get databases to complete the question-
naire, when we did get a response, the completeness of 
information gathered was high and proved useful in identi-
fying their potential to participate in linked research. Meso- 
and macro-level questions were important discriminators 
between use-case and non-use-case eligible data sources. 
There are currently no other survey instruments available to 
enable brokerage between databases potentially willing to 
participate in research. Micro levels informed about the data 
and its granularity.
Implications of the findings
The TIRRE survey is the first step towards assessing 
the potential of a database for linkage. It can identify data 
Pa
ir Name Country URL
Si
ze
 (N
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00
)
Da
te
 es
ta
bl
ish
ed
Primary 
coding 
system
Secondary 
coding 
system
Linkage 
Yes/
Pilot/
Plan/No
Ethics 
approval
Contact 
patients
Months Y/N
Primary Care & Genetic ‘Biobanks’
1 Biobank of 
Medical 
University 
Graz
Austria www.medunigraz.at/
biobank
100–1000 2006 ICD-10 n/a Pilot ≤3 months Yes
Austrian 
Primary Care 
Research 
Network
Austria n/a 10–100 2005 ICPC-2 n/a No ≤3 months No
2 Généthon France www.genethon.fr 10–100 1991 n/a n/a Pilot 4–6 months Yes
OMG 
CONSTANCE 
GAZEL
France 0.1–1 n/a No
3 Da Vinci 
European 
Biobank 
(daVEB)
Italy www.
davincieuropeanbiobank.
org
100–1000 2008 ICD-10 n/a Yes ≤3 months No
Arianna database Italy n/a 10–100 2002 ICD-9 n/a Pilot n/a Yes
4 SGI-RVB Spain www.csisp.gva.es/web/
csisp
10–100 2010 SNOMED 
(CT)
Read 
Codes
Yes ≤3 months Yes
SIDIAP Spain n/a >5000 2005 ICD-10 n/a No ≤3 months No
5 The Wellcome 
Trust Type 
2 Diabetes 
Genetics 
Case-control 
Collection
UK-Scotland www.diabetesgenetics.
dundee.ac.uk
10–100 2004 n/a n/a Yes ≤3 months Yes
Health 
Informatics 
Centre
UK-Scotland n/a 100–1000 1990 ICD-10 SNOMED Yes ≤3 months Yes
Table 5 The eligible sites for conducting the diabetes TRANSFoRm use-cases
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Pa
ir Name Country URL
Si
ze
 (N
/10
00
) Secondary 
coding 
system
Y/N
Linkage 
Yes/
Pilot/
Plan/
No
Ethics 
approval
Contact 
patients
Primary care & cancer registry
1 CroDiab Croatia www.idb.hr/web_english/
crodiab.htm
100–
1000
2000 ICD-10 n/a No No No
Croatian Institute 
for Health 
Insurance
Croatia www.hzjz.hr 1–10 2001 ICD-10 ICPC-2 Yes n/a yes
2 Finnish Cancer 
Registry
Finland www.cancerregistry.fi 1000–
5000
1952 ICD-0-3 SNOMED Yes ≤3 months n/a
Care Register 
for Health 
Care (HILMO) 
Institutions
Finland www.stakes.fi >5000 1961 ICD-10 ICPC-2 Yes ≤3 months
3 Tumorothèque 
Régionale 
de Franche-
Comté
France www.chu-besancon.fr/tumoro 1–10 2005 ICD-10 n/a Pilot 4–6 months Yes
OMG 
CONSTANCE 
GAZEL
France No
4 Bremen Cancer 
Registry
Germany www.krebsregister.bremen.de 100–1000
1994 ICD-10 n/a Pilot ≤3 months Yes
CONTENT Germany www.content-info.org 100–
1000
2005 ICD-10 ICPC-2 Pilot 4–6 months Yes
5 National Cancer 
Registry
Ireland www.ncri.ie n/a 1994 ICD-10 n/a Pilot No Yes
GPMED Ireland www.icgp.ie 100–
1000
2008 ICPC-2 n/a Pilot ≤3 months No
6 Janus Serum 
Bank, Cancer 
Registry, 
Norway
Norway www.kreftregisteret.no/en/ 100–
1000
1951 ICD-10 SNOMED 
(CT&RT)
Yes ≤3 months Yes
Norwegian 
Prescription 
Database
Norway www.norpd.no 1000–
5000
2004 ICD-10 ICPC-2 Yes n/a n/a
7 Spanish DILI 
Registry
Spain www.spanishdili.uma.es 0.1–1 1994 n/a n/a Pilot ≤3 months No
SIDIAP Spain n/a >5000 2005 ICD-10 n/a No ≤3 months No
8 Spanish Tumour 
Bank Network
Spain www.cnio.es 100–
1000
2000 ICD-10 n/a Pilot ≤3 months No
SIDIAP Spain n/a >5000 2005 ICD-10 n/a No ≤3 months No
9 National Cancer 
Intelligence 
Network 
(NCIN)
UK-England www.ncin.org.uk/home.aspx >5000 1971 ICD-10 n/a Yes 4-6 months Yes
General Practice 
Research 
Database 
(GPRD)
UK-England admin@gprd.com >5000 1987 Read 
Codes
n/a Yes ≤3 months Yes
10 SCI-DC, 
Scotland
UK-Scotland 1000–
5000
2005 ICD-10 Read Codes Pilot ≤3 months Yes
Health 
Informatics 
Centre
UK-Scotland n/a 100–
1000
1990 ICD-10 SNOMED Yes ≤3 months Yes
Table 6 The eligible sites for conducting Barrett’s disease TRANSFoRm use-cases
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be conducted. We propose that future projects should con-
sider including incentives in their budget. An effective method 
to reduce the impact of this self-selection bias could be to 
approach databases with a partially completed survey (using 
information available in the public domain) in order to encour-
age participation. Furthermore, the collected data could be 
shared publicly as a metadata registry that would facilitate 
advertising data offered by organisations for prospective 
studies. We also recommend limiting surveys to 30–40 ques-
tions to improve the response rate.
Call for further research
We need to conduct test-retest studies to assess the reli-
ability of the survey instrument. The reliability test could be 
carried out by repeating the data collection after a period 
of time. While this would help to validate the instrument, 
it will also potentially remove any bias introduced by the 
specific person responding to the survey. We should con-
duct simulated and real studies with data extractions to 
test its validity. However, conducting real studies may be 
affected by the availability of funding. Alternatively, we can 
promote reuse of the instrument in other projects with the 
research area.
CONCLUSIONS
A large complex set of data is needed to know if it will be 
possible to link primary care and either disease registry of 
the genetic database. This complex set of data can either 
be classified by level of granularity or as a business or data 
requirement.
The TIRRE instrument is a useful tool that can be used 
to assess general suitability and readiness to participate in 
linked research studies. With increased use, it is likely that 
TIRRE will evolve further, but its use needs to be embedded 
in a concrete ‘offer’ and business case rather than a one-off 
research study.
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sources suitability in terms of data availability and readiness 
to participate in a study. Whilst the initial focus of TIRRE was 
on linking data sources (which were important and consis-
tent), the meso- and macro-factors generally had higher OR 
of predicting use-case eligibility.
Different coding systems have varying levels of granular-
ity. For example, at the time of this study, neither ICD-10 
nor ICPC differentiated between types of diabetes accord-
ing to the latest WHO classification. ICD-10 differentiates 
insulin-dependent and non-insulin-dependent, rather than 
the Type 1 (insulin for survival) and Type 2 diabetes used in 
the latest classifications. Although we acknowledge, this is 
now updated in later releases.
Comparison with the literature
It is possible to draw comparisons between the complexity of 
this task and the existing successful projects that involve link-
ing data. However, the successful data repositories in the UK 
have all been based on a single vendor of GP eHR system. 
Clinical Practice Research Datalink previously only extracted 
data from a single vendor called In-Practice Systems, though 
they are expanding this to all UK vendors;25 Q-Research on the 
EMIS system26 and other UK research networks (The Health 
Improvement Network27 and ResearchOne28) and other net-
works following the same pattern. The only exception to this in 
the UK is the Royal College of General Practitioners (RCGP) 
Research and Surveillance Centre (RSC);29 this network 
extracts data from all the different brand of medical record 
systems. It has published a cohort profile about patients in the 
RCGP RSC database with diabetes, one of the TRANSFoRm 
use-case areas30 Notwithstanding the RSCHP RSC success, 
the relatively simple task of linking data from this small num-
ber of brands of computer within the UK has proved challeng-
ing, both in terms of creating a summary care record31 and in 
developing a common data extraction system.32
Limitations of the method
Any initial screening process will need to be followed up by 
a detailed assessment of whether the dataset needed for a 
given study can be elicited from the data repositories. There 
was no real incentive for data repositories to supply us with 
the data required, as there was not a reciprocal offer of 
benefit. As a consequence, our results inevitably underesti-
mate the number of sites where this type of research can 
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Appendix 1 Details of the TRANSFoRm work tasks
Description of work tasks (WT) 6.1 and 6.2 of the TRANFoRm project:
WT 6.1: Requirements analysis of EHRs
1. Using the results of the EHR capacity study within the EGPRN and ESPCG networks (WT1.1), we will con-
duct an in-depth study of the most common EHRs systems used in Europe to examine the availability of API 
details. The scope of the study will include patient-held records, which may hold substantially less coded and 
structured data. These will include Microsoft and Google patient record systems – and countries where health 
cards are used.
2. We will conduct a parallel in-depth study of data repositories that can be used for clinical trials. We will look 
to identify local, EHR brand specific and health-system access points to primary care data. The types of data-
access points we might be able to run queries on might include: 1) Billing or performance indicator extracts 
of routine data; 2) Sentinel networks or research network database and 3) National data extract systems with 
closed API. These may provide pragmatic quick win access to primary care data while a longer-term access 
is being developed.
WT 6.2: Requirements analysis of genotype data repositories.
We will conduct a parallel in-depth study of (genotype) clinical data repositories across Europe and their 
potential use for clinical research. The scope of the study will include structured genotype data and potential 
integration points with patient healthcare for biomedical and translational clinical research. Genotype data 
is normally held by Biobanks or other research organisations either as sample identification information or 
specific codes for Single Nucleotide Polymorphisms (SNPs).
Level Category Primary care data
Genetic 
database
Cancer 
registry
Others (social care 
data, cohorts)
Number of 
questions
Micro Data source 30–46 36–54 30–46 33–51 54
Data interoperability 30–43 31–43 31–43 31–43 43
Subtotal 60–89 67–97 61–89 64–94 97
Meso Record system 5–30 30
Macro Organisational 15–15 15
Socio-cultural 6–10 10
Subtotal 21–25 25
Study Use-case specific 5–8 8
Total
Min: 91
Max: 152
Min: 98
Max: 160
Min: 92
Max: 152
Min: 95
Max: 157
160
Table S1 Categories of data collection and min-to-max number of questions; skip logic reduces the number of questions 
that each type of respondent might answer
On-line completion of the TIRRE questionnaire
Online Primary care data Genetic data Cancer registry data Total (n)
Partial 21 11 13 45
Valid 12 9 10 31
Total 33 20 23 86
Table S2 Number of contacts and valid responses
Number of contacts and valid responses
Primary care (n) Genetic (n) Cancer registry (n) Total (n)
First contacted by email 110 117 89 316
First contacted by phone 83 19 16 118
Other phone contacts 53 25 17 95
Declined 1 1 0 2
Partial responses 39 14 18 71
Valid responses 29 12 15 56
Table S3 Number of contacts and valid responses
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Number of questions
Primary care Cancer registry Genetic Overall
Analysis by 
respondent
Potential 
maximum 
responses
Mean Response Mean Response Mean Response Mean Response
Categorical 
questions n n % n % n % n %
Data source 35 22.41 64 24.00 69 25.00 71 23.39 67
Data 
interoperability 31 29.34 95 28.80 93 26.25 85 28.54 92
Micro-level 66 51.76 78 52.80 80 51.25 78 51.93 79
Meso-level/record 
system 12  3.10 26  2.33 19  2.67 22  2.80 23
Organisational 15 15.00 100 15.00 100 15.0 92 14.73 98
Socio-cultural 6  5.17 86 5.47 91  4.50 75  5.11 85
Macro-level 21 20.17 96 20.47 97 18.25 87 19.84 94
Overall 104 79.90 76.82 80.60 77.50 83.27 80.07 80.76 77.66
Table S4 Completion of the questionnaire
Is ICPC used? Version Modified
Yes No Don’t Know ICPC-1 ICPC-2 Yes No
n % n % n % n % n % n % n %
Primary care 11 38 17 17 1 3 2 18 9 82 0 0 11 100
Cancer Registry 0 0 12 12 3 20 0 n/a 0 n/a 0 0 0 0
Genetic ‘Biobank’ 0 0 10 10 1 9 0 n/a 0 n/a 0 0 0 0
Total 11 20 39 71 5 9 2 18 9 82 0 0 11 100
Table S6 Coding systems information (ICPC)
Is SNOMED used? Version
Yes No Don’t Know CT RT No Data
n % n % n % n % n % n %
Primary care 3 10 24 83 2 7 1 33 1 33 1 34
Cancer registry 2 13 11 73 2 14 1 33 1 33 1 34
Genetic ‘Biobank’ 2 18 7 64 2 18 2 67 1 33 0 0
Total 7 13 42 76 6 11 4 44 3 33 2 23
Table S7 Coding systems information (SNOMED)
Is ICD used? Version Modified
Yes No Don’t Know ICD-9 ICD-10 No Data Yes (number) No/no data
n % n % n % n % n % n % n % n %
Primary care 20 69 9 31 0 0 3 15 17 85 0 0 5 25 15 75
Cancer registry 12 80 2 13 0 0 1 8 9 75 2 5 3 25 9 75
Genetic ‘Biobank’ 7 64 3 27 1 4 1 14 6 86 0 0 1 14 6 86
Total 39 71 14 25 1 4 5 13 32 82 2 5 9 23 30 77
Table S5 Coding systems information (ICD)
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Are the Clinical 
Terms version 
3 used (CTv3)?
Are Read 
Codes used? None No Data
n % n % n % n %
Primary care 2 6 3 10 25 81 1 3
Cancer registry 0 0 1 7 11 73 3 20
Genetic ‘Biobank’ 0 0 1 9 10 91 0 0
Total 2 4 5 9 46 81 4 6
Table S8 Reading coding systems usage (CTv3 and Read codes version used)
Is there a coding system for drugs? What coding system
Yes No Don’t Know ATC Codes DAAD Multilex Other No Data
n % n % n % n % n % n % n % n %
Primary care 24 83 65 17 0 0 19 79 0 0 2 8 3 13 0 0
Cancer registry 5 33 9 60 1 7 3 60 0 0 1 20 1 20 0 0
Genetic ‘Biobank’ 4 36 6 55 1 9 3 75 0 0 0 0 0 0 1 25
Total 33 60 20 36 2 4 25 76 0 0 3 9 4 12 1 3
Table S9 Coding systems for drugs
Daily dose Frequency Administration 
route
No Data
n % n % n % n %
Primary care 20 35 18 32 19 33 0 0
Cancer registry 3 3 3 30 2 20 2 20
Genetic ‘Biobank’ 0 0 0 0 0 0 4 100
Total 23 32 21 30 21 30 6 8
Table S10 Extraction of drug information from data provided
Routine primary 
care data
Genetic ‘Biobank’ Cancer registry Use-case location
Countries EU N n N n N n Primary Care + 
Genetic/Biobank
Primary Care + 
Cancer Registry
Austria X 5 1 3 1 4 0 X
Belgium X 10 2 3 0 3 0
Bulgaria X 0 0 0 0 0 0
Croatia 1 1 0 0 1 1 X
Cyprus X 0 0 0 0 0 1
Czech Republic X 0 0 0 0 0 2
Denmark X 4 1 1 0 1 0
Estonia X 3 0 0 1 1 0
Finland X 1 1 1 0 1 1 X
France X 11 3 24 1 13 1 X X
Germany X 9 4 18 0 4 1 X
Greece X 4 0 1 0 1 1
Table S11 Location of respondents and eligible sites
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Routine primary 
care data Genetic ‘Biobank’ Cancer registry Use-case location
Countries EU N n N n N n Primary Care + Genetic/Biobank
Primary Care + 
Genetic/Biobank
Hungary X 2 0 0 0 0 0
Iceland 2 0 5 1 2 0
Ireland X 4 1 1 0 1 1 X
Italy X 15 3 27 1 18 0 X
Latvia X 0 0 1 1 1 0
Lithuania X 1 0 1 1 1 0
Luxembourg X 1 0 0 0 0 0
Malta X 1 1 3 0 2 0
Norway 5 1 2 0 2 1 X
Poland X 0 0 1 0 4 1
Portugal X 6 0 2 1 3 1
Romania X 7 0 2 0 1 0
Russia 2 0 0 0 1 0
Slovakia X 1 1 0 0 1 0
Slovenia X 0 0 0 0 1 0
Spain X 17 1 11 1 14 2 X XX
Sweden X 7 1 1 0 1 0
Switzerland 1 1 2 1 9 0
The Netherlands X 24 2 6 0 4 0
Turkey 2 0 0 0 0 0
UK-England X 11 3 3 0 11 1 X
UK-Northern Ireland X 0 0 0 0 1 0
UK-Scotland X 6 1 2 1 1 1 X X
UK-Wales X 0 0 0 0 0 0
European* X 2 0 9 1 1 1
Total 165 29 130 12 111 15 5 10
Table S11 (Continued)
